Access cutting-edge biliary tract cancer treatment through this clinical trial at a research site in Orlando. Study-provided care at no cost to qualified participants.
Access biliary tract cancer specialists in Orlando at no cost
This study follows strict safety protocols and ethical guidelines
All study-related biliary tract cancer treatment provided free
The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract cancer.
Sponsor: Jazz Pharmaceuticals
Check if you qualify for this biliary tract cancer clinical trial in Orlando, FL
If you're searching for biliary tract cancer treatment options in Orlando, FL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Orlando research site is actively enrolling participants for this clinical trial. You'll receive care from experienced biliary tract cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.